To evaluate the impact of depression before autologous and allogeneic hematopoietic cell transplantation (HCT) on clinical outcomes post-transplantation. METHODS: We analyzed data from the Center for International Blood and Marrow Transplant Research to compare outcomes after autologous (n 5 3786) or allogeneic (n 5 7433) HCT for adult patients with hematologic malignancies with an existing diagnosis of pre-HCT depression requiring treatment versus those without pre-HCT depression. Using Cox regression models, we compared overall survival (OS) between patients with or without depression. We compared the number of days alive and out of the hospital in the first 100 days post-HCT using Poisson models. We also compared the incidence of grade 2-4 acute and chronic graft-versus-host disease (GVHD) in allogeneic HCT. RESULTS: The study included 1116 (15%) patients with pre-transplant depression and 6317 (85%) without depression who underwent allogeneic HCT between 2008 and 2012. Pre-transplant depression was associated with lower OS (hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.04-1.23; P 5 0.004) and a higher incidence of grade 2-4 acute GVHD (HR, 1.25; 95% CI, 1.14-1.37; P < 0.0001), but similar incidence of chronic GVHD. Pre-transplant depression was associated with fewer days-alive-and-out-of-the hospital (means ratio [MR] 5 0.97; 95% CI, 0.95-0.99; P 5 0.004). There were 512 (13.5%) patients with Pre-transplant depression and 3274 (86.5%) without depression who underwent autologous HCT. Pre-transplant depression in autologous HCT was not associated with OS (HR, 1.15; 95% CI, 0.98-1.34; P 5 0.096) but was associated with fewer days alive and out of the hospital (MR, 0.98; 95% CI, 0.97-0.99; P 5 0.002). CONCLUSION: Pre-transplant depression was associated with lower OS and higher risk of acute GVHD among allogeneic HCT recipients and fewer days alive and out of the hospital during the first 100 days after autologous and allogeneic HCT. Patients with pre-transplant depression represent a population that is at risk for posttransplant complications.
INTRODUCTION
Depression is associated with increased mortality among otherwise healthy individuals and patients with various medical conditions including cardiovascular disease, cancer, and solid organ transplantation. [1] [2] [3] [4] Hematopoietic cell transplantation (HCT) represents a physically and emotionally challenging therapy, often with a prolonged period of recovery. 5, 6 The psychological burden associated with HCT is well-documented, with increasing rates of depression and anxiety seen up to 5 years post-HCT. [7] [8] [9] However, the relationship between a diagnosis of depression before HCT and clinical outcomes of patients after autologous and allogeneic HCT is not fully understood.
Although a diagnosis of post-transplant depression has been linked to increased mortality, 10 studies exploring the impact of an existing diagnosis of depression before HCT on overall survival (OS) in this population have yielded conflicting results. [10] [11] [12] [13] [14] [15] The inconsistent nature of these findings is partly due to limitations of prior work including mostly single-institution studies with small sample sizes, the inclusion of autologous and allogeneic HCT recipients collectively, inconsistent case ascertainment and timing of such ascertainment, and failure to account for significant confounders. [11] [12] [13] 16 Therefore, larger multicenter studies with robust sample sizes that enable us to examine the association between pre-HCT depression and OS of autologous and allogeneic HCT are necessary to answer this question.
Beyond mortality, the effect of pre-HCT depression on other outcomes, including hospital length of stay and incidence of acute and chronic graft-versus-host disease (GVHD), is currently unknown. Hospital length of stay during the first 100 days post-HCT is an important marker of health care use and has clinical implications for both patients and families. 17 Acute and chronic GVHD are major post-transplant complications in patients undergoing allogeneic HCT with resulting functional limitations, morbidity, and mortality. 9, 12, 13, 18, 19 Importantly, GVHD can often be prevented and treated with immunosuppressive therapy to ensure adequate disease control. 12, 13, [20] [21] [22] Given the association between depression and low medical adherence, 23 it is plausible that pre-HCT depression may affect hospital length of stay during the first 100 days post-HCT as well as the incidence of GVHD.
Defining the effects of pre-HCT depression on posttransplantation outcomes including OS, hospital length of stay, and incidence of acute and chronic GVHD among allogeneic HCT recipients has important implications regarding the diagnosis, management, and psychological support provided for depressed patients undergoing such intensive therapy.
In this study, we analyzed data from the Center for International Blood and Marrow Transplant Research (CIMBTR) to examine the relationship between pre-HCT depression and OS in a large cohort of patients with hematologic malignancies undergoing autologous and allogeneic HCT. We also analyzed the effect of pre-HCT depression on hospital length of stay during the first 100 days after HCT. Finally, we assessed whether pre-HCT depression is associated with the incidence of acute and chronic GVHD in patients undergoing allogeneic HCT. We hypothesized that pre-HCT depression would be associated with lower OS and higher hospital length of stay during the first 100 days in both the autologous and allogeneic HCT settings. Moreover, we hypothesized that pre-HCT depression is associated with higher rates of acute and chronic GVHD.
METHODS

Participants
We analyzed data from the CIBMTR registry to compare outcomes of patients with hematologic malignancies undergoing autologous and allogeneic HCT who had a diagnosis of pre-HCT depression requiring treatment and those without pre-HCT depression. The CIBMTR is a research collaboration between the National Marrow Donor Program/Be The Match and the Medical College of Wisconsin. It comprises a voluntary working group of more than 450 transplant centers worldwide that contribute detailed data on allogeneic and autologous HCT. Participating centers are required to report all transplants consecutively; compliance is monitored by on-site audits, and patients are followed longitudinally. Computerized checks for discrepancies, physicians' review of submitted data, and on-site audits of participating centers ensure data quality. Studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants. The CIBMTR collects an internationally accepted standard data set that contains a number of key variables for all consecutive transplant recipients. Data are collected pre-HCT, 100 days and 6 months after HCT, annually until year 6 after HCT, and biannually thereafter until death.
We examined outcomes of patients undergoing autologous and allogeneic HCT separately. Inclusion criteria for the allogeneic HCT cohort were adult patients with hematologic malignancies undergoing their first allogeneic HCT between 2008 and 2012. For the autologous HCT cohort, we included adult patients with nonHodgkin lymphoma, Hodgkin disease, or multiple myeloma undergoing their first autologous HCT between 2007 and 2012. For participants with multiple myeloma, we only included those receiving melphalan conditioning given that it was used in >97% of such cases. For both autologous and allogeneic HCT, we excluded patients with a history of HCT.
A Diagnosis of Pre-HCT Depression
We determined the presence of pre-transplant or pre-HCT depression based on a question reported in the CIBMTR pre-HCT form specifically asking whether there is "clinically significant depression requiring treatment (yes vs no)." The answer to this question was obtained based on a review of the medical record at each transplantation center. We performed an audit to ensure the quality of the data obtained from this question at transplant centers, which showed 85% accuracy. To further ensure high-quality data were used, we excluded transplant centers with a case volume of >10 transplants who did not report both patients with and without pre-HCT depression.
Definition of Outcomes
The primary objective of this study was to compare OS between patients with or without pre-HCT depression undergoing allogeneic and autologous HCT. Secondary outcomes included length of stay during the first 100 days and the incidence of acute and chronic GVHD among patients receiving allogeneic HCT.
OS was defined as the time from the date of HCT to date of death, with survivors censored at the time of last contact. We evaluated the incidence of grade 2-4 acute GVHD according to the Glucksberg grading criteria, 24 and chronic GVHD according to the National Institutes of Health chronic GVHD consensus criteria 25 as reported to the CIBMTR. We censored patients at date of subsequent HCT or last follow-up. Length of stay was captured as total days of hospitalization (initial admission and any readmission) between day 0 (day of HCT) and day 1 100 post-HCT. Patients who die early after HCT have less time at risk for hospitalization and shorter length of stay than those who survive to day 100 and beyond. To account for this association of early mortality with shorter hospitalization, we used the number of days alive and out of the hospital as the metric for comparing length of stay in the first 100 days. For patients who died within 100 days post-HCT, we evaluated the number of days of survival out of the hospital. For patients who survived through day 100, we censored follow-up at that time point. We then evaluated the proportion of days alive and out of the hospital. The CIBMTR has used this approach to examine hospital length of stay during first 100 days after allogeneic HCT in previous studies. 17 
Statistical Analysis
We analyzed the data of patients undergoing autologous and allogeneic HCT separately. We compared clinical characteristics for patients with and without pre-HCT depression using a chi-square test for categorical variables and the Wilcoxon rank sum test for continuous variables. We estimated the probability of OS using the KaplanMeier method with a log-rank test for univariate comparisons. We used a cumulative incidence function to account for competing risks when estimating the incidence of grade 2-4 acute GVHD and chronic GVHD. Death without GVHD was treated as a competing risk.
We used Cox proportional hazards regression models to compare OS between patients with or without pre-HCT depression while controlling for significant patient-, disease-, and treatment-related variables. We forced a main effect of pre-HCT depression into the model. The remaining covariates were included using a backward selection technique with a value of P 0.05 as the criterion for inclusion in the final models.
In the multivariate OS allogeneic HCT analysis, the variables that were considered in the model included age, sex, region of HCT center, performance status, race, education, income, marital status, work status, smoking history, diagnosis, disease risk index, 26 time from diagnosis to HCT, conditioning regimen intensity, receipt of TBI, year of HCT, graft type, donor source, donor age, degree of HLA match, donor-recipient sex match, recipient cytomegalovirus status and GVHD prophylaxis regimen. We also examined whether comorbidities (obesity, cardiovascular disease, pulmonary disease, combination of comorbidities) may moderate outcomes between patients with or without pre-HCT depression. We built the models with or without comorbid conditions and we examined the interaction between pre-HCT depression and the comorbidities of interest, but found no significant interactions.
In the multivariate OS autologous HCT analysis, the variables that were considered in the model included age, sex, region of HCT, performance status, race, education, income, marital status, work status, smoking history, diagnosis, disease status at the time of HCT, time from diagnosis to HCT, conditioning regimen, and year of Original Article HCT. We also built the models with or without comorbidities and explored the interaction of pre-HCT and comorbidities of interest.
In a similar fashion, we used Cox proportional hazards regression models to examine the effect of pre-HCT depression on acute and chronic GVHD among allogeneic HCT recipients. Model building proceeded as described previously for OS analysis. We again built the models with or without comorbid conditions and examined the interaction between pre-HCT depression and the comorbidities of interest, but found no significant interaction.
We used multivariate analysis using Poisson regression to compare mean time (in days) that patients were alive and out of the hospital within the first 100 days between patients with or without pre-HCT depression while controlling for significant patient-, disease-, and treatment-related variables. The total number of days alive (up to 100) was used as an offset term in Poisson regression to account for differential exposure time of the patients. The same variables that were described in OS analysis were considered in this model. We constructed 2 separate models for autologous and allogeneic HCT, respectively. The results are summarized as means ratios for comparing groups; a means ratio > 1 indicates more days alive and out of the hospital. We performed all analyses using SAS version 9.3. All P values are 2-sided, and a value of P 5 0.05 was considered statistically significant.
RESULTS
Allogeneic HCT Participants
Among 7433 allogeneic HCT patients, 1116 (15%) had a history of depression requiring treatment (Table 1) . Patients with pre-transplant depression were more likely to be women and had a lower performance status compared with those without pre-HCT depression.
Patients with pre-HCT depression had a higher prevalence of obesity, smoking, cardiovascular disease, and pulmonary disease. No differences between the 2 groups were noted in terms of diagnosis, disease risk, time from diagnosis to HCT, year of HCT, graft type, or donor source.
Autologous HCT Participants
Among 3786 patients, 512 (13.5%) had pre-HCT depression requiring treatment (Table 2 ). There were no differences between the 2 groups in terms of age, region of HCT, diagnosis, disease status at the time of HCT, time from diagnosis to HCT, conditioning regimen, or year of HCT. Patients with pre-HCT depression (vs without depression) were more likely to be female and have a lower performance status. They were also more likely to have comorbidities such as smoking, obesity, cardiovascular disease, and pulmonary disease.
Allogeneic HCT Outcomes Table 3 summarizes the unadjusted analyses comparing allogeneic HCT outcomes between those with and without pre-HCT depression. Participants with pre-HCT depression had lower OS compared with those without pre-HCT depression (Fig. 1A) . The 3-year OS was 40% (95% confidence interval [CI], 37%-43%) for those with pre-HCT depression versus 45% (95% CI, 44%-47%) for patients without depression (P 5 0.002). Patients with pre-HCT depression also had a higher 100-day incidence of grade 2-4 acute GVHD (46% [95% CI, 43%-49%] vs 39% [95% CI, 38%-40%]; P < 0.001) (Fig. 1B) , but no difference in chronic GVHD at 3 years (P 5 0.80).
In multivariable models, pre-HCT depression was associated with lower OS (relative risk [RR], 1.13; 95% CI, 1.04-1.23; P 5 0.003), higher incidence of grades 2-4 acute GVHD (RR, 1.24; 95% CI, 1.14-1.37; P < 0.0001), and fewer days alive and out of the hospital during the first 100 days (MR, 0.97; 95% CI, 0.95-0.99; P 5 0.004). Pre-transplant depression was not associated with chronic GVHD in multivariate analyses (Table 4) . Similar results were obtained when controlling for comorbidities in the multivariate analyses. There were no significant interactions between comorbidities (obesity, cardiovascular disease, or pulmonary disease) and pre-HCT depression.
Autologous HCT Outcomes
In the unadjusted analyses, pre-HCT depression was associated with lower OS among autologous HCT recipients. The 3-year OS between patients with pre-HCT depression versus those without pre-HCT depression was 67% (95% CI, 63%-72%) versus 73% (95% CI, 72%-75%) (P 5 0.01) ( Table 3 , Fig. 2 ). However, after adjusting for significant variables, pre-HCT depression was not associated with OS in multivariate analyses (RR, 1.15; 95% CI, 0.98-1.34; P 5 0.09) ( Table 4 ). Pre-HCT depression was associated with fewer days alive and out of the hospital during the first 100 days (MR, 0.98; 95% CI, 0.97-0.99; P 5 0.002).
DISCUSSION
Among patients undergoing allogeneic HCT, a diagnosis of pre-transplant depression was associated with lower OS, higher risk of acute GVHD, and lower proportion of days spent alive and out of the hospital during the first 100 days after HCT. Among autologous HCT recipients, pre-transplant depression was not associated with OS but was associated with a lower proportion of days spent alive and out of the hospital. Therefore, patients with a diagnosis of depression before HCT represent a population that is at high risk for post-HCT complications, and they may benefit from more intensive interventions to improve their post-HCT outcomes. This is the largest multicenter study of allogeneic HCT recipients to confirm an association between pretransplant depression and lower OS. The difference in OS between patients with pre-HCT depression and those without depression is clinically relevant (5% absolute difference), and it persists despite controlling for many potential confounders and comorbidities. Interestingly, we did not detect a difference in OS among autologous HCT recipients with or without pre-HCT depression. This may partly explain the discrepant findings reported in the literature, as outcomes of patients undergoing autologous and allogeneic HCT are often analyzed collectively. 10, [14] [15] [16] 27 To our knowledge, we are the first to report an association between pre-HCT depression and higher incidence of acute GVHD in patients undergoing allogeneic HCT. It is unclear how pre-HCT depression could affect the incidence of acute GVHD. Possible explanations include differences in health behaviors such as adherence and medical follow-up among depressed versus nondepressed individuals, 23 and/or psychobiological processes resulting in systematic shift in immune activation favoring the development of acute GVHD. [28] [29] [30] Previous research has shown an association between depression and elevation in inflammatory cytokines such as tumor necrosis factor a, and a shift toward a T helper 1 immune response, 31 which in turn is thought to play a role in the pathophysiology of acute GVHD. 32 Future research should focus on understanding the mechanism of association between pre-HCT depression and the increased risk of acute GVHD.
We also report higher health care use, as measured by days spent alive and out of the hospital, among patients with pre-HCT depression compared with those without depression in both the allogeneic and autologous HCT settings. In a previous single-center study, a diagnosis of any mood, anxiety, or adjustment disorder was associated with longer hospital length of stay during HCT admission. 6 Our findings illustrate that differences in resource use among depressed and nondepressed individuals persist up to 100 days after HCT. Possible explanations include the tendency for depressed individuals to present with multiple physical complaints, 6, 33, 34 health behaviors that result in more hospitalizations (eg, nonadherence), 23 and/ or psychobiological processes having an adverse effect on immunologic function after HCT. 28, 29 Although our findings do not establish a causal relationship between pre-HCT depression and higher resource use, they are hypotheses-generating and point to the need for future research.
Our study has several limitations. First, we did not use a validated measure to assess the presence of pre-HCT depression. However, the question regarding pre-HCT depression reported to the CIBMTR has inherent face and content validity. To overcome reporter bias, we excluded transplant centers with >10 transplants who did not report both depressed and nondepressed patients to the registry. Notably, the ascertainment of these cases through the CIBMTR would bias toward the null hypothesis with potential cross-contamination between the 2 groups. Given the lack of large multicenter studies examining this topic, this study represents the first attempt to better understand the relationship between pre-HCT depression and important clinical outcomes after HCT. Second, we are unable to ascertain whether patients with a history of pre-HCT depression were actively receiving or had received any therapy in the past. Third, it is possible that differences in illness severity and other factors could confound the relationship between pre-HCT depression and OS. Nonetheless, pre-HCT depression remained a significant predictor of OS after adjusting for potential confounders. Fourth, although we report on the association between pre-HCT depression and worse post-transplant outcomes, we were unable to determine the mechanism of this association. Finally, we are unable to comment on the association between pre-HCT depression and risk of relapse or nonrelapse mortality. Given the heterogeneity of the population, and because the disease risk index 26 has only been validated when examining OS to control for such heterogeneity, we made an a priori decision to not explore the association between pre-HCT depression and relapse or nonrelapse mortality.
In conclusion, patients with a reported diagnosis of depression before allogeneic HCT had lower OS, higher incidence of grade 2-4 acute GVHD, and spent fewer days alive and out of the hospital during the first 100 days Original Article after HCT. Among autologous HCT recipients, pretransplant depression was not associated with OS but was associated with fewer days spent alive and out of the hospital during the first 100 days after HCT. These findings highlight the potential impact of pre-transplant depression on important post-transplant outcomes including mortality, post-transplant complications, and health care use. Importantly, we identify patients with pre-HCT depression as a vulnerable population who may benefit from specialized interventions to improve their post-transplant outcomes.
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